{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:48:06Z","timestamp":1791686886660,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006518","name":"University of Nebraska Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006518","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003750","name":"French Association for Alzheimer Disease and Similar Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejmech.2026.118670","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:39:45Z","timestamp":1770943185000},"page":"118670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Access to novel potent pleiotropic prodrugs, targeting both butyrylcholinesterase and serotonin reuptake, with anti-amnesic activities in Alzheimer's disease model"],"prefix":"10.1016","volume":"307","author":[{"given":"Valentin","family":"Travers--Lesage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Crouzier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjana","family":"Antonijevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Toublet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Modeste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Brazzolotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Nachon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Since","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangui","family":"Maurice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7996-2082","authenticated-orcid":false,"given":"Christophe","family":"Rochais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-615X","authenticated-orcid":false,"given":"Patrick","family":"Dallemagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejmech.2026.118670_bib1","article-title":"Alzheimer's disease drug development pipeline: 2025","volume":"11","author":"Cummings","year":"2025","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118670_bib2","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1021\/acs.jmedchem.3c00541","article-title":"Dual-acting small molecules: subtype-selective cannabinoid receptor 2 agonist\/butyrylcholinesterase inhibitor hybrids show neuroprotection in an alzheimer's disease mouse model","volume":"66","author":"Spatz","year":"2023","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2026.118670_bib3","doi-asserted-by":"crossref","first-page":"17378","DOI":"10.1021\/acs.jmedchem.5c00933","article-title":"Targeting neuroinflammation and cognitive decline: first-in-class dual butyrylcholinesterase and P38\u03b1 mitogen-activated protein kinase inhibitors","volume":"68","author":"Ferjan\u010di\u010d Benetik","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118670_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118071","article-title":"Discovery of a highly selective BChE inhibitor with concomitant anti-neuroinflammatory activity for treating alzheimer's disease","volume":"299","author":"Zhao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118670_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14814","article-title":"The selective butyrylcholinesterase inhibitor UW-MD-95 shows symptomatic and neuroprotective effects in a pharmacological mouse model of alzheimer's disease","volume":"30","author":"Carles","year":"2024","journal-title":"CNS Neurosci. Ther."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118670_bib6","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3390\/ph18081214","article-title":"Unlocking therapeutic potential of novel thieno-oxazepine hybrids as multi-target inhibitors of AChE\/BChE and evaluation against alzheimer's disease: in vivo, in vitro, histopathological, and docking studies","volume":"18","author":"Oudah","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118670_bib7","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1039\/D2MD00087C","article-title":"Novel benzimidazole-based pseudo-irreversible butyrylcholinesterase inhibitors with neuroprotective activity in an alzheimer's disease mouse model","volume":"13","author":"Spatz","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118670_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117986","article-title":"Multitarget-directed carbamate and carbamothioate derivatives: cholinesterase and monoamine oxidase inhibition, Anti-\u03b2-Amyloid (A\u03b2) aggregation, antioxidant and blood-brain barrier permeation properties against alzheimer's disease","volume":"298","author":"Teke Tuncel","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118670_bib9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/17460441.2022.2031972","article-title":"Advances in prodrug design for alzheimer's disease: the state of the art","volume":"17","author":"Travers--Lesage","year":"2022","journal-title":"Expert Opin. Drug Discov."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118670_bib10","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bmcl.2005.11.031","article-title":"Designing rapid onset selective serotonin Re-Uptake inhibitors. Part 1: structure-activity relationships of substituted (1S,4S)-4-(3,4-Dichlorophenyl)-N-Methyl-1,2,3,4-Tetrahydro-1-Naphthaleneamine","volume":"16","author":"Middleton","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118670_bib11","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/jpp\/rgaf041","article-title":"Targeting together cholinesterases and serotonin reuptake against alzheimer's disease","volume":"77","author":"Guiselin","year":"2025","journal-title":"J. Pharm. Pharmacol."},{"issue":"14","key":"10.1016\/j.ejmech.2026.118670_bib12","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.3390\/molecules30143047","article-title":"Design, synthesis, and evaluation of 1-Benzylpiperidine and 1-Benzoylpiperidine derivatives as dual-target inhibitors of acetylcholinesterase and serotonin transporter for alzheimer's disease","volume":"30","author":"Gonz\u00e1lez-Guti\u00e9rrez","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118670_bib13","author":"Middleton"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118670_bib14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118670_bib15","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1111\/bcp.14690","article-title":"Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in alzheimer's disease","volume":"87","author":"Chr\u00e9tien","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118670_bib16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0925-4439(02)00071-6","article-title":"Antidepressants inhibit human acetylcholinesterase and butyrylcholinesterase activity","volume":"1587","author":"M\u00fcller","year":"2002","journal-title":"Biochim. Biophys. Acta BBA - Mol. Basis Dis."},{"key":"10.1016\/j.ejmech.2026.118670_bib17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41594-018-0026-8","article-title":"Structural basis for recognition of diverse antidepressants by the human serotonin transporter","volume":"25","author":"Coleman","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"15","key":"10.1016\/j.ejmech.2026.118670_bib18","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.3390\/molecules24152786","article-title":"Inhibiting acetylcholinesterase to activate pleiotropic prodrugs with therapeutic interest in alzheimer's disease","volume":"24","author":"Toublet","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118670_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113059","article-title":"Pleiotropic prodrugs: design of a dual butyrylcholinesterase inhibitor and 5-HT6 receptor antagonist with therapeutic interest in alzheimer's disease","volume":"210","author":"Toublet","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118670_bib20","article-title":"Lectins: methods and protocols","volume":"1200","author":"Hirabayashi","year":"2014"},{"issue":"14","key":"10.1016\/j.ejmech.2026.118670_bib21","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/cmdc.201600223","article-title":"A novel way to radiolabel human butyrylcholinesterase for positron emission tomography through irreversible transfer of the radiolabeled moiety","volume":"11","author":"Sawatzky","year":"2016","journal-title":"ChemMedChem"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118670_bib22","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3390\/molecules22111828","article-title":"Bacterial expression of human butyrylcholinesterase as a tool for nerve agent bioscavengers development","volume":"22","author":"Brazzolotto","year":"2017","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118670_bib23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/1471-2105-11-405","article-title":"OpenChrom: a cross-platform open source software for the mass spectrometric analysis of chromatographic data","volume":"11","author":"Wenig","year":"2010","journal-title":"BMC Bioinf."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118670_bib24","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1021\/acs.analchem.5b00140","article-title":"Bayesian deconvolution of mass and ion mobility spectra: from binary interactions to polydisperse ensembles","volume":"87","author":"Marty","year":"2015","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejmech.2026.118670_bib25","series-title":"Schr\u00f6dinger Release 2023-4: Protein Preparation Wizard","year":"2023"},{"key":"10.1016\/j.ejmech.2026.118670_bib26","series-title":"Schr\u00f6dinger Release 2023-4","year":"2023"},{"key":"10.1016\/j.ejmech.2026.118670_bib27","series-title":"Schr\u00f6dinger Release 2023-4: Glide","year":"2023"},{"key":"10.1016\/j.ejmech.2026.118670_bib28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0006-8993(95)01032-7","article-title":"Amnesia induced in mice by centrally administered 13-amyloid peptides involves cholinergic dysfunction","volume":"706","author":"Maurice","year":"1996","journal-title":"Brain Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T13:42:20Z","timestamp":1775482940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426001157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":28,"alternative-id":["S0223523426001157"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118670","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Access to novel potent pleiotropic prodrugs, targeting both butyrylcholinesterase and serotonin reuptake, with anti-amnesic activities in Alzheimer's disease model","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118670","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118670"}}